SAN DIEGO, Oct. 6, 2016 /PRNewswire/ -- Mark L. Baum, CEO and founder of Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), and James Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), will debate the motion that "Big Pharma Prioritizes Profits Over Patients" at the prestigious Oxford Union Debating Society at Oxford University on October 20, 2016 at 8:30 p.m. local time.
Mr. Baum will be debating in support of the motion with Sir Richard Thompson KCVO, the former personal physician to the Queen and past President of the Royal College of Physicians, London, along with an Oxford student debater. Joining Mr. Greenwood for the opposition will be Dr. Ken Powell, Chairman of ReViral, a UK biotech company, and an Oxford student debater. The debate will be available for viewing several weeks following the event on the Oxford Union's YouTube channel, which has almost 35 million views since being re-launched in a new format earlier this year.
The Oxford Union is the world's most prestigious speaker and debating society, with an unparalleled reputation for bringing international guests and speakers to Oxford. Its Thursday debates began in 1823 as an act of defiance at a time when free speech was under threat in England. Past speakers at the Oxford Union have included Presidents Reagan, Nixon and Carter, Nancy Pelosi, David Cameron, Malcolm X, Mother Teresa, the Dalai Lama, Anna Wintour, Michael Jackson, Sir Elton John, Shakira, Morgan Freeman, Albert Einstein, Stephen Hawking, and Buzz Aldrin.
"It is a great honor to participate in the Oxford Union tradition of debating important issues of the day, and in this case, an issue that affects the daily lives of so many Americans," stated Mark L. Baum. "Although there are many pharmaceutical companies saving and extending lives through investments in new drug development, it is the lack of competition for many old, off-patent, well-characterized FDA-approved drugs that has resulted in rapid and excessive price increases for many critical medicines in the U.S. The combination of the high and growing prices of drugs that lack competition, increasing annual out-of-pocket costs for drug benefit deductibles, and the increasing number of drugs in short supply is causing what amounts to a healthcare crisis for millions of Americans. As an advocate of patient access to affordable and innovative medications through safe drug compounding, I look forward to a lively debate at this renowned international forum."
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to producing and dispensing high quality innovative compounded medications in all 50 states. The company's unique business model drives patient access and affordability to many critical medications. Headquartered in San Diego, California, Imprimis owns and operates three production and dispensing facilities located in California, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
All Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-ceo-mark-l-baum-to-debate-at-the-oxford-union-debating-society-300340344.html
SOURCE Imprimis Pharmaceuticals, Inc.